Volunteer Recruitment and Laboratory Facilities Expansion
Open Orphan PLC (AIM:ORPH) Trading Update and screening facilities expansion
Open Orphan PLC (AIM: ORPH) Appointment of Chief Executive Officer
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the
Open Orphan PLC (AIM: ORPH) FDA Breakthrough Designation for Big Pharma RSV
Vaccine candidate assessed in successful human challenge trial conducted by hVIVO
Open Orphan PLC (AIM: ORPH) Positive results from RSV Human Challenge Study
Data on Phase 2a study published in New England Journal of Medicine
Open Orphan plc (AIM: ORPH) Launch of STRiVE project
Respiratory viral strains suitable for challenge agents being collected from consenting volunteers
Open Orphan PLC (ORPH.L) World’s first COVID-19 Characterisation Study
Results from the world’s first COVID-19 Characterisation Study Data shows SARS-CoV-2 human challenge studies are safe in healthy young adults
Poolbeg Pharma PLC (POLB.L) Confirmation of vaccine platform licence execution
31 January 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, confirms that it has signed the licence
Open Orphan PLC (ORPH.L) Malaria Human Challenge Model Launched
First volunteers inoculated with Malaria human challenge virus
UK economy will outpace the rest of G7 and cast off omicron’s shadow
The UK’s economy will outpace all other nations in the G7 in 2022, for the second year in a row. It is roaring back after a deep recession than many
Open Orphan PLC (ORPH.L) £5m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) $13.4m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a
